Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 3/2005

01-10-2005

Combination Therapy with Thalidomide, Incadronate, and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Authors: Naoya Ochiai, Noriko Yamada, Ryo Uchida, Shin-ichi Fuchida, Akira Okano, Mayumi Hatsuse, Masashi Okamoto, Eishi Ashihara, Chihiro Shimazaki

Published in: International Journal of Hematology | Issue 3/2005

Login to get access
Metadata
Title
Combination Therapy with Thalidomide, Incadronate, and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Authors
Naoya Ochiai
Noriko Yamada
Ryo Uchida
Shin-ichi Fuchida
Akira Okano
Mayumi Hatsuse
Masashi Okamoto
Eishi Ashihara
Chihiro Shimazaki
Publication date
01-10-2005
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 3/2005
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1532/IJH97.05049

Other articles of this Issue 3/2005

International Journal of Hematology 3/2005 Go to the issue

OriginalPaper

Arsenic Trioxide Therapy in Relapsed or Refractory Japanese Patients with Acute Promyelocytic Leukemia: Updated Outcomes of the Phase II Study and Postremission Therapies

OriginalPaper

The Expression of Telomeric Proteins and Their Probable Regulation of Telomerase during the Differentiation of All-trans-Retinoic Acid-Responsive and -Resistant Acute Promyelocytic Leukemia Cells

OriginalPaper

Cyclin D1 Gene Polymorphism and Susceptibility to Childhood Acute Lymphoblastic Leukemia in a Chinese Population

Letter to the Editor

Nephrotic Syndrome with Extensive Mesangiolysis as a Clinical Manifestation of Chronic Graft-versus-Host Disease (GVHD)

OriginalPaper

Hepatitis C Virus Infection in Adult Chinese Hemophilia Patients Negative for the Human Immunodeficiency Virus: Treatment Results with Interferon and Ribavirin

Case Report

The Application of Molecular Analyses for Primary Granulocytic Sarcoma with a Specific Chromosomal Translocation
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits